A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Inclusion Criteria: * Participant must be 18 to 79 years of age inclusive, at the time of signing the informed consent * Renally Impaired Participants and Disease Characteristics * Mildly or moderately decreased renal function, as assessed by estimated glomerular filtration rate (eGFR). Mildly impaired renal function: eGFR: 60 up to 89 mL/min/1.73 m\^2 (inclusive); Moderately impaired renal function: eGFR: 30 up to 59 mL/min/1.73 m\^2 (inclusive) * Stable renal disease, i.e. a serum creatinine value determined 3 or more months before screening (e.g. during routine diagnostics) should not differ by more than 25% from the serum creatinine value determined at screening * Participants with normal renal function: Normal renal function, as assessed by eGFR ≥90 mL/min/1.73 m\^2 * Body mass index (BMI) within the range 18 - 40 kg/m\^2 (inclusive) * Body weight (bw) ≥ 45 kg * Study participants of reproductive potential must agree to use adequate contraception when sexually active. * Male participants must agree not to donate sperm from the signing of the ICF until the follow-up visit on Day 12 (± 2d). Exclusion Criteria: * Any relevant disease (other than those related to renal impairment for the renal impaired participants) within 4 weeks prior to study drug administration including infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation) requiring medical treatment * Acute renal failure or acute nephritis within the past 2 years * Febrile illness within 1 week before study drug administration * Malignancy diagnosed or treated within the past 5 years (hepatocellular carcinoma within the past 2 years). This does not include adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin * Conditions associated with a risk of hypersensitivity reactions as judged by the investigator * Any participant not able to produce urine and/or needing dialysis * Dialysis for acute renal failure within the previous 6 months prior to administration of study intervention * Contrast agent administration within one month prior to screening or during the screening period * Indication for immunosuppressants, receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy within 6 months prior to administration of study intervention * Clinically relevant abnormalities in physical examination, ECG, clinical chemistry, hematology, or urinalysis as judged by the investigator * Heart rate below 45 bpm or above 110 bpm * Systolic blood pressure below 90 mmHg or above 170 mmHg * Diastolic blood pressure below 45 or above 105 mmHg * Indication or evidence for long QT syndrome for all participants; additionally for participants with normal renal function: QT interval corrected using Fridericia's method (QTcF) \> 470 msec * History of COVID-19 within 6 months prior to screening * Long COVID-19 syndrome or other clinically relevant COVID-19-related symptoms or sequela * Incomplete SARS-CoV-2 vaccination * Vaccination planned before completion of the last study visit